Medtech Insight RSS Feed - Commercial

Europe’s Biotech Edge Lies In Science-First Investing

Lucie Ellis-Taitt — Thu, 02 Apr 2026 07:40:43 +0000

For Matthieu Coutet, the path into venture capital began not in finance, but inside the machinery of scientific innovation. Starting his career in tech transfer at Inserm’s commercialization arm, Cout

Insilico’s CEO On AI, Drug Novelty And Beating China Biotech At R&D

Wed, 01 Apr 2026 15:33:15 +0000

Some 12 years after setting up Insilico Medicine, its CEO and founder Alex Zhavoronkov believes his company is at the forefront of an artificial intelligence-led revolution in biopharma R&D. But w

BioBytes: AI-Related Deals In Q1 ‘26

Sushmita Panda — Wed, 01 Apr 2026 08:14:18 +0000

AI-focused M&As, partnerships and financings in the biopharma industry had a strong start to the year with a mix of jumbo financing rounds, IPOs and big-ticket pharma alliances. Earendil Labs’ $78

Factors Driving Change For Medtechs And Biotechs – A Legal View

Ashley Yeo — Wed, 01 Apr 2026 07:28:54 +0000

“We had the boom years of 2020 and 2021, then we had the ‘less busy’ years, and now hopefully the markets are coming out the other side.” That is how Sophie McGrath, partner at legal firm Goodwin, tee

M&A: South Korean Firms Shift To Factories Before Pipelines

Mainbayar Badarch — Mon, 30 Mar 2026 08:43:28 +0000

In 2025, South Korea saw significant pharmaceutical M&A activity as companies expanded globally and strengthened manufacturing capabilities. Samsung Biologics acquired its first US drug production

BioBytes: AI-Related Deals In Q4 ‘24

David Wild — Mon, 30 Mar 2026 07:04:26 +0000

BioBytes presents an overview of select AI-focused M&As, partnerships and financings in the biopharma industry in Q4 2024. Of note are a $1.05bn partnership between Roche and Dyno Therapeutics and

Daiichi Sankyo Looks To Deploy ‘Smarter’ R&D Approach To ADCs

Jessica Merrill — Wed, 25 Mar 2026 16:32:25 +0000

Daiichi Sankyo has been one of the pioneers in the development of antibody-drug conjugates (ADCs) for the treatment of cancer. While the Japanese pharma has had notable successes in the field, most ob

Could CAR-T Cells Cure Some Autoimmune Diseases?

Melanie Senior — Wed, 25 Mar 2026 07:57:25 +0000

Some cancer drugs are being redeployed in autoimmune disease, with early evidence of dramatic, durable effects. Gilead’s $7.8bn acquisition of Arcellx – one of the year’s biggest deals so far – provid

The Commercial Test: Psychedelics Move From Fringe Science To Doctor’s Office

Manas Mishra — Wed, 25 Mar 2026 07:56:15 +0000

As psychedelic therapies approach their first potential regulatory approvals, an unusual set of questions has taken center stage: Few people have witnessed the medicalization of psychedelics as closel

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

Edwin Elmhirst|Lucie Ellis-Taitt — Mon, 23 Mar 2026 21:09:00 +0000

This examination of global market trends and the overall structure of the oncology sector sets the stage. Oncology is the pharmaceutical industry’s largest therapeutic area, representing about 18% of

Practicalities For AI-Enabled Devices As Digital (R)evolution Picks Up Pace

Ashley Yeo — Mon, 23 Mar 2026 08:35:14 +0000

Digital and AI-enabled medical device innovators are learning new codes of regulatory compliance while at the same time developing software engineering and data science expertise, overseeing steering

Chugai’s Narrow Partnering Strategy Means Less Competition

Mandy Jackson — Mon, 23 Mar 2026 08:33:32 +0000

Chugai Pharmaceutical opened a partnering office in South San Francisco in January to give the company better access to discovery technologies and drug targeting capabilities developed by US biotechno

Execs On The Move: February 2026

In Vivo Team — Wed, 18 Mar 2026 11:06:27 +0000

Adapt To Survive: Private Hospitals In A High-Pressure Landscape

Ashley Yeo — Wed, 18 Mar 2026 11:05:42 +0000

Private hospitals know that value creation opportunities are there for the taking, but they are often unsure of which levers to pull for maximum success within their organization. So said Jean-Philipp

An Irregular Regulatory Agency: Industry Contends With An Unpredictable FDA

Alaric DeArment — Wed, 18 Mar 2026 10:56:39 +0000

For decades, the US Food and Drug Administration has served as the gold standard for biopharmaceutical regulation and the world’s foremost arbiter of which drugs are safe and effective. But the second

Astellas Bets On Degradation Over Inhibition In Race To Crack KRAS G12D

David Wild — Mon, 16 Mar 2026 16:47:39 +0000

For decades, KRAS was the oncology field’s most wanted and most elusive target. The G12C mutation finally fell to covalent inhibitors. G12D – which is more prevalent in pancreatic and colorectal cance

The Autonomous Lab: Part 2

David Wild — Mon, 16 Mar 2026 14:03:37 +0000

Part 1 of this feature examined the competing architectural philosophies behind the autonomous lab – from Ginkgo’s flexible cart system to LabGenius’s deliberately rigid platform, Iktos’s pivot to

Deals In Depth: February 2026

Maureen Riordan|Deanna Kamienski — Mon, 16 Mar 2026 13:54:28 +0000

The companies will incorporate each other’s complementary strengths to accelerate global development of novel medicines. Leveraging its antibody technology platforms, Innovent will oversee program dev

Podcast: Onchilles Pharma’s Neutrophil-Derived Path To Pan-Cancer Therapy

David Wild — Thu, 12 Mar 2026 06:47:16 +0000

What if a cancer drug could kill tumor cells broadly, leave the immune system intact, and then recruit it as a weapon? That is the biological logic behind the ELANE pathway, a mechanism Lev Becker unc

At The Immune Frontier, The Hardest Questions Are Commercial

David Wild — Wed, 11 Mar 2026 21:24:24 +0000

Hans Keirstead had barely finished his opening remarks at a panel on “immune frontiers” when he announced that Immunis Inc. had just unblinded its Phase II trial minutes before he took the stage. The